摘要
目的探讨奈达铂与顺铂联合5-氟尿嘧啶方案同步放化疗治疗中晚期宫颈癌患者的疗效和安全性。方法选择我院于2010年7月—2012年3月确诊的中晚期宫颈癌患者78例,根据化疗药物的不同分为A组39例(奈达铂同步放化疗法)和B组39例(顺铂+5-氟尿嘧啶同步放化疗法)。观察与评价两组放化疗3个月内的近期疗效、随访2年内的远期疗效及毒副作用。结果两组的近期生存率、远期生存率、远期转移率和远期复发率比较,差异均无统计学意义(P>0.05)。A组Ⅲ度胃肠道反应和Ⅲ度白细胞减少的发生率均低于B组,差异有统计学意义(P<0.05)。结论两种方案治疗中晚期宫颈癌的疗效相近,但患者对奈达铂同步放化疗法的耐受性更好。
Objective To investigate the efficacy and safety of nedaplatin with concurrent radiotherapy in the treatment of cervical cancer in middle and late periods. Methods A total of 78 patients with cervical cancer in middle and late periods treated in our hospital between July 2010 and March 2012 were selected. They were divided into group A （ concurrent nedaplatin chemotherapy and radiotherapy） （n = 39） and group B （concurrent PF regimen and radiotherapy） （n = 39）. The short -term and long - term efficacy and adverse reactions in the two groups in three months after chemoradiotherapy and 2 years of follow - up were observed and evaluated. Results There was no significant difference in the rates of recent survival, long - term survival, long - term metastasis and long - term recurrence between two groups （ P 〉 0.05 ）. The incidences of leukopenia in Grade III and gastrointestinal reactions in Grade III in group A were significantly lower than those of group B （P 〈 O. 05）. Conclusion The two regimens in the treatment of cervical cancer in middle and late periods have similar efficacy. But patients have higher tol- erance to the cocurrent nedaplatin chemotherapy and radiotherapy.
出处
《中国全科医学》
CAS
CSCD
北大核心
2013年第32期3849-3850,3853,共3页
Chinese General Practice
关键词
奈达铂
顺铂
5-氟尿嘧啶
宫颈肿瘤
同步放化疗
Nedaplatin
Cisplatin
5 - fluorouracil
Uterine cervical neoplasms
Concurrent chemoradiotherapy
